Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06448910
Status:
RECRUITING
Last Update Posted:
2024-07-08
First Post:
2024-06-04
Brief Title:
CadonilimabAK104 Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced Unresectable Stage III NSCLC
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
Lung-AK104 Study CadonilimabAK104 Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced Unresectable Stage Lll Non-Small Cell Lung Cancer
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this single arm phase II clinical trial is to evaluate the efficacy and safety of cadonilimab AK104 as induction and consolidation therapy in locally advancedunresectable non-small cell lung cancer NSCLC patients treated with concurrent chemoradiotherapy
Participants will receive 2 cycles of induction therapy with cadonilimab combined with carboplatincisplatin plus etoposide followed by standard concurrent chemoradiotherapy thoracic radiotherapy carboplatincisplatin plus etoposide regimen chemotherapy and finally consolidation therapy with cadonilimab AK104 for 1 year
Participants will receive 2 cycles of induction therapy with cadonilimab combined with carboplatincisplatin plus etoposide followed by standard concurrent chemoradiotherapy thoracic radiotherapy carboplatincisplatin plus etoposide regimen chemotherapy and finally consolidation therapy with cadonilimab AK104 for 1 year
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None